C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2026)
C4 Therapeutics (CCCC) recorded quarterly Change in Account Payables of -$85000.0 in Q1 2026, up 81.99% quarter-over-quarter from -$472000.0 in Q4 2025, and up 86.82% on a YoY basis from -$45497.9 in Q1 2025.
C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2026) Analysis & Trends
C4 Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$85000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 86.82% year-over-year to -$85000.0; the TTM figure through Mar 2026 stood at $92000.0 (up 109.73% YoY), while the FY2025 annual figure was -$468000.0, down 293.28% from the prior year.
- Change in Account Payables was -$85000.0 for Q1 2026 at C4 Therapeutics, up from -$472000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.5 million in Q2 2025 to a low of -$1.7 million in Q3 2022.
- Historically, Change in Account Payables has averaged -$219529.4 across 5 years, with a median of -$176000.0 in 2024.
- Biggest YoY gain for Change in Account Payables was 314.55% in 2025; the steepest drop was 454.4% in 2025.
- A 5-year view of Change in Account Payables shows it stood at -$1.1 million in 2022, then surged by 115.71% to $169000.0 in 2023, then plunged by 204.14% to -$176000.0 in 2024, then slumped by 168.18% to -$472000.0 in 2025, then surged by 81.99% to -$85000.0 in 2026.
- The last three Change in Account Payables figures came in at -$85000.0 (Q1 2026), -$472000.0 (Q4 2025), and -$885000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | C4 Therapeutics | 451.35 Mn | 215.68 Mn | - | -85,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85,000.00 |
| Mar 31, 2026 | -85,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Jun 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | -645,000.00 |
| Mar 31, 2025 | -645,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 169,000.00 |
| Dec 31, 2023 | 169,000.00 |